公开(公告)号：US12269840B2

公开(公告)日：2025-04-08

申请号：US17299087

申请日：2019-12-03

Applicant: Bristol-Myers Squibb Company

Inventor： Michael Anthony Schmidt ,  Bin Zheng ,  Benjamin M. Cohen ,  Amanda J. Rogers ,  Changxia Yuan ,  Jason J. Zhu ,  Chao Hang ,  Daniel S. Treitler ,  Adam Joseph Freitag ,  Geoffrey Eugene Purdum ,  Miao Yu ,  Melda Sezen Edmonds ,  Siwei Guo

IPC: C07H21/00 ,  C07H1/00 ,  C07H19/16 ,  C07H19/20

Abstract: The invention generally relates to an improved processes for the preparation of a cyclic dinucleotide which is useful as a STING agonist of the following formula (I), involving the use of compounds A and B.

公开(公告)号：US20250092012A1

公开(公告)日：2025-03-20

申请号：US18948828

申请日：2024-11-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joshua Hansen ,  Mimi L. Quan

IPC: C07D401/04 ,  A61K45/06 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14

Abstract: Provided herein are compounds having the formula I for treating, preventing or managing cancer. Also provided are pharmaceutical compositions comprising the compounds and methods of use of the compounds and compositions. In certain embodiments, the methods encompass treating, preventing or managing cancer, including solid tumors and blood borne tumors using the compounds provided herein.

公开(公告)号：US20250074909A1

公开(公告)日：2025-03-06

申请号：US18928275

申请日：2024-10-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04

Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US20250066344A1

公开(公告)日：2025-02-27

申请号：US18718477

申请日：2022-12-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Sreekantha Ratna Kumar ,  Pitani Veera Venkata Srinivas ,  Subramanya Hegde ,  Michael J. Orwat

IPC: C07D417/12 ,  A61K31/357 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/423 ,  A61K31/424 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/437 ,  A61K31/438 ,  A61K31/443 ,  A61K31/4525 ,  A61K31/4725 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/675 ,  C07D261/20 ,  C07D317/48 ,  C07D405/12 ,  C07D413/12 ,  C07D413/14 ,  C07D487/04 ,  C07D491/107 ,  C07D495/04 ,  C07D495/10 ,  C07D498/04 ,  C07D498/10 ,  C07D513/04 ,  C07F9/6558

Abstract: The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).

公开(公告)号：US20250059610A1

公开(公告)日：2025-02-20

申请号：US18818366

申请日：2024-08-28

Applicant: Bristol-Myers Squibb Company

Inventor： Prabhu Seshaiyer BHAGAVATHEESWARAN ,  Nicholas Allan John BOTWOOD ,  Han CHANG ,  Yali FU ,  William J. GEESE ,  George A. GREEN ,  Diane HEALEY ,  Sabine MAIER ,  Faith E. NATHAN ,  Abderrahim OUKESSOU ,  Giovanni SELVAGGI ,  Joseph Daniel SZUSTAKOWSKI

IPC: C12Q1/6886

Abstract: The disclosure provides a method for treating a subject afflicted with a tumor, e.g., lung cancer, having a high tumor mutation burden (TMB) status comprising administering to the subject an immunotherapy, e.g., an anti-PD-I antibody or antigen-binding portion thereof. The present disclosure also provides a method for identifying a subject suitable for an immunotherapy, e.g., a treatment with an anti-PD-I antibody or antigen-binding portion thereof, comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-I antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.

公开(公告)号：US12227576B2

公开(公告)日：2025-02-18

申请号：US18161713

申请日：2023-01-30

Applicant: Bristol-Myers Squibb Company

Inventor： Robin Edwards ,  William J. Geese ,  Danielle M. Greenawalt

IPC: C07K16/28 ,  A61P35/00

Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.

公开(公告)号：US12226451B2

公开(公告)日：2025-02-18

申请号：US17257530

申请日：2019-07-02

Applicant: Bristol-Myers Squibb Company

Inventor： Thomas Palm ,  Mehrnaz Khossravi ,  Sanket Patke

IPC: A61K38/18 ,  A61K9/00 ,  A61K9/08 ,  A61K47/22 ,  A61K47/26 ,  A61K47/54 ,  A61K47/60 ,  A61K47/64 ,  A61K47/68

Abstract: The present application provides pharmaceutical formulations comprising a FGF-21 polypeptide, e.g., a modified FGF-21 polypeptide such as PEG-FGF-21, and one or more stabilizers such as the chelator DPTA. The formulations can be can further stabilized by including a surfactant such as polysorbate 80 and/or adjusting the pH to about 7.1. Also provided are methods of manufacture, methods of treatment, and kits.

公开(公告)号：US20250049765A1

公开(公告)日：2025-02-13

申请号：US18718484

申请日：2022-12-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Andrew K. Dilger ,  Leon M. Smith ll ,  Michael J. Orwat ,  Donald J.P. Pinto

IPC: A61K31/423 ,  A61K31/27 ,  C07C237/24 ,  C07D261/04 ,  C07D261/20

Abstract: The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).

公开(公告)号：US20250026767A1

公开(公告)日：2025-01-23

申请号：US18908888

申请日：2024-10-08

Applicant: Bristol-Myers Squibb Company

Inventor： Roxana F. Schlam ,  Nicolas Cuniere ,  Victoria A. Mbachu ,  Zhongping Shi ,  Petinka I. Vlahova

IPC: C07D513/04 ,  A61K31/433 ,  A61K45/06 ,  A61P7/02 ,  C07C55/10 ,  C07C59/265

Abstract: The present invention relates to co-crystals of the compound of formula (I). wherein the co-former molecule is succinic acid or citric acid. processes for the preparation of the co-crystal. pharmaceutical compositions thereof, and methods of using the co-crystals for treating or preventing thromboembolic disorders.

公开(公告)号：US20250011288A1

公开(公告)日：2025-01-09

申请号：US18701270

申请日：2022-10-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Adam James Clarke ,  Todd J. Friends ,  Arvind Mathur ,  Michael C. Myers ,  Jianqing Li ,  Donald J. P. Pinto ,  Kumar Balashanmuga Pabbisetty ,  Shun Su ,  Benjamin P. Vokits ,  Durga Buchi Raju Barre ,  Leon M. Smith, II ,  Michael J. Orwat ,  Scott A. Shaw ,  Sreekantha Ratna Kumar ,  Hima Kiran Potturi

IPC: C07D213/82 ,  A61K31/343 ,  A61K31/353 ,  A61K31/381 ,  A61K31/415 ,  A61K31/416 ,  A61K31/42 ,  A61K31/423 ,  A61K31/424 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5383 ,  A61K31/541 ,  C07D215/54 ,  C07D217/02 ,  C07D217/04 ,  C07D217/08 ,  C07D231/18 ,  C07D231/22 ,  C07D231/54 ,  C07D237/24 ,  C07D239/34 ,  C07D241/24 ,  C07D261/04 ,  C07D307/00 ,  C07D311/24 ,  C07D333/38 ,  C07D401/06 ,  C07D405/12 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D491/107 ,  C07D498/04

Abstract: The disclosure relates to compounds of Formula (I), which arm RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension). Formula (I)